Envisagenics

Envisagenics, a spinoff of the Cold Spring Harbor Laboratory (CSHL), focuses on the discovery and development of RNA splicing therapeutics using its AI-driven platform, SpliceCore. The platform identifies novel RNA splicing events that cause cancer and other genetic diseases, which can then be used for target discovery, biomarker discovery, and identification/testing of potential therapeutics (internally and in partnership with other institutions). 

As of February 2024, the company had seven programs targeting oncology and neurogenerative diseases, all of which were in their research and preclinical stages. 

Key customers and partnerships

Envisagenics partnered with Bristol-Myers Squibb in November 2022 to accelerate the identification of alternative splicing-derived targets for cancer. Prior to that, in May 2021, the company partnered with Biogen to advance ribonucleic acid (RNA) splicing research for central nervous system (CNS) diseases and Johnson & Johnson in April 2020 to build predictive models for lung cancer progression and risk.

Funding and financials

In August 2022, the company received a USD 2 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) (as part of the National Institutes of Health [NIH]) to accelerate the commercialization of the company’s AI platform, SpliceIO, and advance the company’s pipeline of immuno-oncology targets.